clinical research companies denmark

9 biotech companies leading the way in Denmark

Known for being one of the happiest countries in the world, Denmark has become a big hub for biotech in Europe . In this article, we take a look at 9 of the best biotech companies headquartered in Denmark.

In the last few years, Denmark’s life sciences sector has accelerated its output of high-quality research, as the country was ranked 16th overall for biological sciences-related output in 2022. The country is also among the fastest-growing nations in Europe for biotech investment , hitting $434 million in 2021.

Following the example of Danish pharma giant Novo Nordisk – which on its own has helped to raise Denmark’s gross domestic product (GDP) after the success of its weight loss drug , Wegovy – many biotech companies in Denmark are striving to bring forth the next big breakthrough in the biopharma industry. Here are 9 biotech companies in Denmark leading innovation in the sector. 

Table of contents

Acesion pharma .

Based in Copenhagen in Denmark, Acesion is a cardiovascular biotech company that focuses on developing therapies for atrial fibrillation (AF), the most common type of cardiac arrhythmia. More specifically, it is working on the development of small molecule SK inhibitors. These inhibit SK channels, which are ion channels present in the heart that help regulate cardiac rhythm.

The company currently has two candidates in its pipeline. Its lead therapy is called AP30663 and is an SK ion channel inhibitor for conversion of AF to normal sinus rhythm, delivered through an intravenous infusion. Last year, a phase 2 trial of AP30663 met its primary endpoint , which was the proportion of patients with AF conversion to sinus rhythm within 90 minutes of infusion start. 

Acesion is developing its other candidate, AP31969, for the maintenance of sinus rhythm in patients with AF. In September last year, the company raised €45 million ($49 million) in series B funding, the proceeds of which will be used to advance the clinical development of AP31969 and progress it into a phase 1 trial and completion of a phase 2 trial. 

Adcendo is working on harnessing the uPARAP receptor to develop antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need. The uPARAP receptor was originally identified as a novel target and cloned by the scientific founders of Adcendo. It is a key player in the body’s management of the extracellular matrix, particularly in collagen remodeling. It is essential for tissue repair and maintenance but also happens to be overexpressed in several cancer types. 

Suggested Articles

Six biotech companies in south korea you should know about, five latest advancements in tourette’s syndrome research, six biotech companies that could revolutionize obesity treatments, five cleantech companies making new zealand more green, 10 unusual applications of crispr gene editing.

In April last year, the ADC company announced the completion of a series A extension financing, raising a further €31 million ($33 million) following a €51 million ($55 million) series A financing in April 2021. At the time, Adcendo said it intended to use the proceeds from this financing to initiate a broad clinical development program for uPARAP ADC in sarcoma, and it also said it was planning to advance the development of its second ADC pipeline asset with Development Candidate Nomination (DCN) planned in H1 2024.

Then, the following month, in May 2023, the Denmark-based company also announced that it had expanded its current collaboration with Duality Biologics, a biotech company also focusing on the discovery and development of next-generation ADC therapeutics. This agreement is part of Adcendo’s strategy to further develop its ADC pipeline and the collaboration aims to utilize Duality’s capabilities to potentially enhance Adcendo’s existing ADC technologies.

Ascendis Pharma 

Ascendis Pharma is a biotech company based in Hellerup, Denmark, focused on the development of improved treatments that address unmet medical needs. The company has a platform technology called TransCon that allows it to slow down the release of a drug once inside the body, which can significantly reduce the frequency of injections needed to treat a chronic condition. 

TransCon refers to “transient conjugation,” which is the ability to temporarily link an inert carrier to a parent drug with known biology. Depending on the carrier used, TransCon prodrugs can be designed to act systemically or locally, focused on meeting a specific therapeutic goal. TransCon is widely applicable to proteins, peptides, or small molecules in multiple therapeutic areas.

Ascendis has a pipeline focused on oncology and rare diseases involving endocrinology. In 2021, it had its first product approved by the U.S. Food and Drug Administration (FDA), named SKYTROFA, which is a treatment for pediatric growth hormone deficiency. People with this rare disease require daily injections and many patients are known to skip doses during the week due to the high frequency currently required. However, Ascendis’ treatment only has to be taken once a week, reducing the burden for patients. 

Ascendis also recently announced that the European Commission had approved another one of its products, called YORVIPATH, for the treatment of adults with chronic hypoparathyroidism, a rare condition where the parathyroid glands, which are in the neck near the thyroid gland, produce too little parathyroid hormone.

Bavarian Nordic 

Bavarian Nordic works in the vaccine space, focusing on the development, manufacturing, and commercialization of life-saving vaccines. It is a global leader in smallpox vaccines and has been a long-term supplier to the U.S. government of a non-replicating smallpox vaccine, which has been approved by the FDA , and is also intended to protect against monkeypox. The vaccine is also approved as a smallpox and monkeypox vaccine in Canada and as a smallpox vaccine in Europe . Additionally, the company’s commercial product portfolio contains vaccines against rabies, tick-borne encephalitis, cholera, and typhoid.

The company has built its foundation around poxviral-based vaccine platform technologies, and in particular, its proprietary technology, Modified Vaccinia Ankara – Bavarian Nordic (MVA-BN). MVA-BN is an adaptable platform suitable for addressing a wide variety of infectious diseases and cancers. It is a further attenuated version of the Modified Vaccinia Ankara (MVA) virus, which is a highly attenuated strain of the poxvirus Chorioallantois Vaccinia virus Ankara (CVA).

Bavarian Nordic also has two primary products in its development pipeline at the minute. One is a Chikungunya virus virus-like particle (VLP)-based vaccine, which is in phase 3 clinical development for active immunization against Chikungunya disease. The other candidate is a multi-valent vaccine candidate developed under contracts with the U.S. government to address the unmet medical need for a vaccine against western, eastern, and Venezuelan equine encephalitis viruses, which are rare, but potentially deadly viruses transmitted to humans by mosquitoes.

Founded in 1999 in Denmark, international biotech company Genmab has invented next-generation antibody technology platforms and leveraged translational, quantitative, and data sciences, resulting in a pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies, and antibody-drug conjugates. To help develop and deliver novel antibody therapies to patients, Genmab has formed more than 20 strategic partnerships with biotechnology and pharmaceutical companies, such as AbbVie, Janssen, Amgen, and BioNTech. 

Genmab already has some of its products (developed in collaboration with other companies) on the market. These include Darzalex (daratumumab), which has become a blockbuster drug for the treatment of multiple myeloma, Arzerra (ofatumumab), which is indicated for chronic lymphocytic leukemia (CLL), Tivdak (tisotumab vedotin-tftv), for previously treated recurrent or metastatic cervical cancer, and Epkinly (epcoritamab-bysp), for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma. In total, Genmab says there are eight approved therapies incorporating its antibody technology.

The company also has more than 20 products currently in clinical development, as its vision is to transform the lives of people with cancer and other serious diseases by 2030 with knock-your-socks-off (KYSO) antibody medicines. 

Hoba Therapeutics

Hoba Therapeutics is developing restorative treatments for chronic pain disorders and hearing loss. Both indications have a clear unmet medical need for safe and efficacious treatments for millions of patients worldwide. 

The company’s lead candidate is HB-086 for the treatment of chronic neuropathic pain. It is a non-opioid compound with a unique mechanism of action targeting the peripheral nervous system to reverse neuropathic pain and the underlying cause of the disease. Meanwhile, Hoba’s second drug candidate is called HB-097, which is a pharmacological treatment for sensorineural hearing loss. Preclinical data of HB-097 show both a preventive effect of hearing loss by protecting nerve cells and a regenerative effect by reversal of already induced damage.

In December 2023, Hoba managed to raise €23 million ($25 million) in a series A financing first close. The company said it will use the proceeds from this round to advance HB-086 through late pre-clinical development to the completion of phase 1 clinical studies in patients with painful Chemotherapy-Induced Peripheral Neuropathy (CIPN). The indication has been selected as a gateway indication into chronic neuropathic pain disorders and is a painful, often debilitating condition caused by cancer treatment with certain chemotherapy drugs.

IO Biotech is a player in the immuno-oncology field and is developing therapeutic cancer vaccines based on its T-win cancer vaccine platform. The company uses peptides to modulate the activity of T cells to not only eliminate cancer cells but also immunosuppressive cells that release signals that weaken immune activity. The result is a stronger immune response against the tumor.

The company’s lead candidate, IO102-IO103, combines two of IO Biotech’s wholly-owned T-win vaccines, IO102 and IO103, that are designed to activate and expand T cells specific for IDO and PD-L1, respectively. IDO and/or PD-L1 are overexpressed by many types of solid tumors and immune-suppressive cells (Tregs and TAMs) in the tumor microenvironment (TME). By combining IO102 and IO103, the candidate is intended to have a synergistic effect on cells in the TME that express IDO and/or PD-L1, leading to enhanced cell killing.

Based on positive phase 1/2 first-line advanced melanoma data, IO102-IO103, in combination with Merck’s checkpoint inhibitor pembrolizumab, has been granted a breakthrough therapy designation for the treatment of unresectable/metastatic melanoma by the FDA. IO Biotech recently completed the enrollment of 380 patients in a pivotal phase 3 trial for IO102-IO103 in advanced melanoma. 

As an antibiotic resistance company based in Copenhagen, Denmark, biotech MinervaX was established to develop a prophylactic vaccine against group B Streptococcus (GBS) based on research from Lund University. It is currently developing a GBS vaccine for maternal immunization since GBS can cause a potentially fatal infection in newborn infants. The company’s vaccine is different from other GBS vaccine candidates in development, which are generally based on traditional capsular polysaccharide (CPS) conjugate technology, as it is a protein-only vaccine based on fusions of highly immunogenic and protective protein domains from selected surface proteins of GBS. 

The vaccine is currently in phase 2 trials. Initial data from two phase 2 studies in 470 pregnant people has demonstrated that the vaccine has an acceptable safety profile, is highly immunogenic, and gives rise to functionally active antibodies. The vaccine is also being explored in a phase 1 trial in older adults, where GBS causes significant illness, such as sepsis, pneumonia, cellulitis, and soft tissue infections. 

At the end of last year, MinervaX raised €54 million ($58.9 million) in upsized financing, enabling it to progress its GBS vaccine toward phase 3 clinical trials at some point in 2024.

Zealand Pharma

Working on the development of next-generation peptide therapeutics, Zealand Pharma specializes in treatments for rare diseases, as well as obesity, which is proving to be an extremely popular field at the moment since the approval of weight loss and diabetes drugs Wegovy and Ozempic last year. More than 10 drug candidates invented by Zealand have advanced into clinical development. Two have been already approved and are marketed by Sanofi and Novo Nordisk, and three candidates are in late-stage development. 

The Danish biotech company’s two most advanced candidates are dasiglucagon and glepaglutide. Dasiglucagon is a long-acting GLP-2 analog that the company is currently seeking FDA approval in patients aged seven days or older with congenital hyperinsulinism (CHI), a genetic disorder in which the pancreas secretes too much insulin. Glepaglutide is also a long-acting GLP-2 analog that is in phase 3 of development for the treatment of short bowel syndrome, a condition in which the body cannot absorb enough nutrients from foods because part of the small intestine is missing or damaged.

Zealand Pharma also announced positive data last month, for its experimental weight-loss drug that it is developing with Boehringer Ingelheim, as a phase 2 trial showed that 83% of adults treated with the therapy achieved “groundbreaking” results in liver disease due to metabolic dysfunction-associated steatohepatitis (MASH), with significant improvements in fibrosis. This announcement was so significant that it made the company’s shares soar by 34%.

Thorough investment in life sciences in Denmark 

The Danish government invests substantially in research and development in Denmark, as it funds the academic sector, as well as the Danish National Research Foundation, which is an independent research-funding body established by the Danish parliament in 1991. The foundation hands out close to $70 million a year to fund basic research, and more than one-third of this is focused on the life sciences industry. On top of government funding, there is also a considerable amount of international investment in the sector. Ultimately, the combination of public and private investment is a major factor in the recent success of Denmark’s life sciences industry.

This article was originally published in June 2018 by Clara Rodríguez Fernández and has since been updated by Willow Shah-Neville in March 2024.

Partnering 2030: The Biotech Perspective 2023

Latest Articles

Hypoparathyroidism: rare endocrine disorder garners attention from biopharma in 2024, six bispecific antibody companies you should know about, what is abcam’s founder, jonathan milner, up to, how biotech startups become unicorns.

• Executive Management
• Board of Directors
• Our Publications
• Upcoming Events

Welcome to Sanos Group

Full circle clinical research and development, we provide first-class clinical research.

Sanos Group is a Full Circle Clinical Research and Development Organization encompassing six independent business units: NBCD , Sanos Clinic , Sanos Supply , Studies&Me , Blueskin and Omicron .

We are headquartered in Soborg outside Copenhagen, Denmark, where we share the building with NBCD, Blueskin and Omicron.

All business units in the Sanos Group are dedicated to providing first-class clinical research, aiming to keep improving and develop how we conduct innovative clinical trials for our clients and patients. We play a critical role in developing new medication and treatment options, and work diligently to bring new medication faster to the patients.

We are acknowledged for our scientific expertise, and long track record of efficient and innovative clinical trials.

Sanos Group is an organization in rapid development, which means that we rely on our agility and efficiency. At present, Sanos Group consists of around 200 employees, and we are experiencing continuous growth.

• Acquisitions
• Other Stuff
• Event Overview
• Get Tickets
• Startup Sourcing
• Premium Reports
• Startup Database
• Investor Database
• Mission / Team
• Advertising
• Our Newsletter
• Register Now
• CLUB Benefits

77 Top Biotechnology Startups and Companies in Denmark (2021)

This article showcases our top picks for the best Biotechnology companies based in Denmark. These startups and companies are taking a variety of approaches to innovating the Biotechnology industry, but are all exceptional companies well worth a follow.

We tried to pick companies across the size spectrum from cutting-edge startups to established brands. We selected these startups and companies for exceptional performance in one of these categories:

• Innovation: Innovative ideas, innovative route to market, innovative product
• Growth: Exceptional growth, exceptional growth strategy
• Management and Societal Impact

Top Biotechnology Startups in Denmark

Data sourced from  Crunchbase  and  SemRush .

By the way : If you’re a corporate or investor looking for exciting startups in a specific market for a potential investment or acquisition, check out our Startup Sourcing Service!

• biotechnology
• Blue Biotechnology

Barcelona-based Impress secures over €110 million to expand orthodontic services across Europe

London-based ifast diagnostics secures over 5.9 million to combat antimicrobial resistance globally, weekly funding round-up all of the european startup funding rounds we tracked this week (oct 21 – oct 25), cardiff-based antiverse secures €4.2 million to advance generative ai antibody design, vienna-based flinn.ai secures €10 million to automate quality and regulatory medtech compliance, applications for eit digital champions 2025 are now open: paving the way for european deep tech scaleups to succeed, munich-based medtech symphera secures €2.4 million to streamline surgical procedures, from fiction to function: 10 european startups pushing the boundaries of robotics, swedish medtech amferia snaps €1.2 million to combat resistant bacterial infections, most popular, polish startup cellis wins the 2024 innovation radar prize with breakthrough immunotherapy innovation, brussels-based voxreality awards €1 million to boost accessibility in extended reality projects, eu-startups podcast | episode 95: sophia velastegui former microsoft chief ai officer, toulouse-based openairlines secures nearly €45 million to accelerate sustainable aviation solutions.

EU-Startups.com is the leading online magazine about startups in Europe. Learn more about us and our advertising options .

© Menlo Media S.L. - All rights reserved.

A European Full-Service CRO 

Our mission is to plan, conduct, analyse, and report all of our projects – big or small  – with the same approach and attention to the delivery of high-quality services and product development.

Direct Operations

Clinical trials, years of experience.

Smerud Medical Research Group

​ Smerud Medical Research Group (SMERUD) is a leading, commercial clinical Contract Research Organisation (CRO) providing full-service clinical trial services to biotech, pharma, med-tech, and academic sponsors.  We primarily operate in Northern Europe with headquarters in Norway and subsidiary offices in Denmark, Finland, Sweden, the United Kingdom, Germany, Austria, and Poland. Thus, our clients will benefit from our local presence and point of contact and full access to our firm’s expertise and experience. We are very proud of our highly competent and well-educated staff, most of whom could claim seniority in the business of drug development.

We look at professional pride as a key value and our promise to clients and employees is that we will always adhere to premium business ethics and aim to deliver first-class quality in all our services.  Being innovators and entrepreneurs  in several areas, we remain committed to our corporate vision: ‘Semper excelsior’.

We deliver quality through best-in-class procedures, highly educated specialists, and a strong belief in the role we play in the field of human care.

Clinical Operations

Our experience is that a strong scientific background with a passion for detail orientation and critical reviewing are mandatory skills to deliver a world-class proof-of-concept study.

Regulatory Affairs

We provide regulatory expertise in the complex regulatory landscape and the many variations in policies and practices of different countries and sites.

Data Management

Our data management unit delivers high-quality data that are validated as per regulatory requirements and industry standards.

Medical Writing

Medical Writing is a service undertaken by our qualified scientists, all with a PhD in a life science related subject, a strong command in English, and/or with proven high-level writing skills.

— Proven track Record —

.      over 600 successful clinical trials conducted with excellence in over 70 therapeutic areas..

Oncology | Dermatology | Cardiovascular | Rheumatology | Psychiatry | Vaccination | Lung diseases

Rare disorders | Urology | Gastroenterology | Gynaecology | Neurology | Chronic kidney disease

We use cookies to provide you a better user experience on this website. Cookie Policy

• Licensing of medicines
• Authorisation procedures
• Company authorisations and registrations
• Supervision and inspection
• What is a clinical trial?
• Questions and answers
• Regulation for Clinical Trials
• Substantial modifications
• Assessment times
• GMP and Quality of IMP
• Non-clinical regulatory advice
• Safety reporting during clinical medicinal trials
• Transition of clinical trials from Directive to Regulation
• Fees for clinical trials
• Combined studies with a clinical trial and a simultaneous performance study
• Decentralised Clinical Trials
• Ongoing clinical trials under the Directive
• End of trials with medicinal products and reporting of results
• Trials in animals
• GCP inspection
• Publications
• How to evaluate evidence of the efficacy of medicines
• Evaluation of reviews
• Report suspected illegal activities
• Falsified medicines
• Compassionate use
• Medicine or not
• Export certificates
• Name/address changes
• Relationships
• Financial support
• Medicinal Products Committee
• Side effects of medicines
• Additional monitoring
• News on pharmacovigilance
• Biological and biosimilar medicinal products
• Safety updates
• Post Authorisation Safety Study
• Direct Healthcare Professional Communication
• Adverse events
• Drug interaction
• Pharmacovigilance Council
• Find medicines
• General reimbursement
• Individual reimbursement
• Calculate reimbursement
• Medicines bought in another EU/EEA country
• Reimbursement Committee
• The EU HTA regulation
• Prices of medicines
• Product numbers
• Central Reimbursement Register
• Reimbursable nutritional products
• Sale outside pharmacies
• Over-the-counter medicines
• Substitution
• Medicines imported from abroad
• Buying and selling medicines online
• Sale of medicines or food supplements online
• Doctors buying medicines for use in their own practices
• Report suspected illegal sale of medicines
• Prescriptions from another country
• Incident reporting
• New regulations
• COVID-19 antigen test for self-test
• Advice to consumers on buying face masks
• New Tech – new technological possibilities and medical devices
• Patient safety and safe medical devices
• Development of medical devices
• Regulatory advice for medical device companies
• Notified bodies
• Registration and marketing
• Clinical investigations
• Performance studies of in vitro diagnostic medical devices (IVDs)
• Certificates of Free Sale
• Legislation and guidance
• Veterinary medicines
• Natural medicinal products and vitamin and mineral products
• Euphoriant substances
• Medical gases
• Radiopharmaceuticals
• Medicines affecting the ability to drive
• Medicinal cannabis
• Regulation of innovative medicinal products including ATMP
• Mission, vision and strategy
• Organisation
• Whistleblowing scheme of the Danish Medicines Agency
• The Danish Medicines Agency funding
• Management of conflicts of interest
• Transparency in the Danish Medicines Agency
• Data protection policy
• Targets and tasks
• International collaboration
• Digital services
• About this site
• Social media
• Subscribe to news
• Edit subscription
• Unsubscribe
• News categories
• Our newsletter DKMA Update
• Order publications

Clinical trials with medicinal products

You must accept marketing cookies to share the page by mail

Share by mail

Conducting well-designed and safe clinical trials is essential for building knowledge about medicines and is a key part of approving new, effective and safe medicines. In addition, clinical trials play a vital role in creating an attractive and competent environment for pharmaceutical development and research in Denmark. Clinical trials provide early insight into new medical treatments in the healthcare system, which builds competence and most importantly benefits patients by giving them quick access to new innovative treatments. Our Clinical Trials Unit is dedicated to improving the clinical trial framework in Denmark and the EU in collaboration with stakeholders from across the ecosystem, always with the best interests of patients in mind. Our focus is to deliver timely and high-quality reviews while developing guidance to support the conduct of clinical trials of the future. You can read more about what a clinical trial is here.

Denmark must be in the lead in early phase research

We have an eye for the entire pharmaceutical development process, but believe that Denmark has the potential to excel in the development of new trial designs, trials with more complex medicines related to rare diseases or personaliced medicines, and early phase research, including 'First in Human' (FIH) trials. This is partly due to Denmark's skilled and specialised researchers and Denmark's many technological opportunities. Early phase trials give Danish patients access to the latest therapies and builds a crucial knowledge capacity among both authorities and researchers. This is expected to have a knock-on effect in the later phases of pharmaceutical development. We are continuously working on initiatives to support early research. We have strong capabilities to support the transition from toxicology studies to clinical trials and offer scientific advice on toxicological, clinical and regulatory issues. In addition, work is underway to re-establish the expedited review of phase I trials under the Clinical Trials Regulation.

The Danish experience makes a difference in Europe

We have a high level of representation and activity in working groups under the European Commission, the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA). In 2024, we have special focus on implementation/optimization of processes under the new EU regulation and the interface between the development of medical devices and medicines.

Increased focus on non-reporting, including trial completion and publication of results

In 2023, we highlighted non-reporting in clinical trials with a stringent process for reminders that can ultimately lead to a police report. Fortunately, there was no need to do so, as we managed to rectify the cases through dialog with the sponsors who failed to make the legally required reports. There has been a significant improvement and we will continue this focus in 2024 to ensure patient safety and transparency of trial results, which is critical for both the research community and patients.

Clinical Trials Unit

+45 44 88 91 23

Send an email

05 November 2024

23 october 2024, 10 june 2024.

• Notifications about clinical trials

Questions about GCP

If you have questions about GCP, see our inspectors' page on GCP and inspections

Amgen: Denmark - a preferred location for clinical trials and research

Amgen invests heavily in innovative medicines, transformative research and world-class bio-manufacturing. Amgen is present in approximately 100 countries reaching millions of people in the fight against serious illnesses.

In 2019, Amgen acquired the Copenhagen-based biopharmaceutical company Nuevolution, now known as Amgen Research Copenhagen. The acquisition of Nuevolution and its DNA-encoded library platform radically expanded Amgen’s small molecule screening capability.

Denmark is one of Amgen’s preferred locations for running clinical trials. This brings important experimental therapies to Danish patients with no other treatment options available, while also contributing valuable knowledge to the research community in Denmark.

"Denmark has a strong position in Amgen when it comes to competing with other countries on where the clinical trials should be placed. This is based on the fact that Denmark has a long tradition for clinical research and a lot of interest and experience in this field. Consequently, sites in Denmark typically deliver trial data of high quality and within agreed timelines. Despite our small size, Amgen Denmark is in the top league and that is definitely something to be proud of." Birgitte Claudius Medical Director, Amgen Denmark

"The fact that Amgen has chosen Denmark as one of its preferred locations for clinical trials will undoubtedly strengthen the clinical research in Denmark for the benefit of patients, the healthcare system and companies. Invest in Denmark is confident that the partnership between Amgen and Trial Nation will contribute to a ensuring that Denmark remains one of the leading European countries in clinical research." Maria Nilaus Tarp Director, Invest in Denmark 

Support from Invest in Denmark

Join denmark’s life sciences cluster and turn clinical research into business.

"We need strong and innovative Public-Private Partnerships to make Denmark an even more attractive place to run clinical research. Therefore, we are very happy to work with our peers in Trial Nation with the common goal of strengthening the clinical trial activities in Denmark. It’s very successful. Denmark has a lot of opportunities to build on and it is fantastic to see how far we get by working together. I see a great future with huge foreign investments in Danish clinical research, because we are continuously developing our research environment and business framework." Birgitte Claudius Medical Director, Amgen Denmark

Get to know Amgen

Get in touch want to know more about clinical trials in denmark.